GLP-1 Receptor Agonists
Definition
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of incretin-based therapies that mimic endogenous GLP-1 to stimulate insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite. They are approved for type 2 diabetes management and (at higher doses) for chronic weight management. Multiple agents in the class have demonstrated cardiovascular and/or nephroprotective benefits in dedicated outcome trials.
Key Concepts
Mechanism of Action
- Bind GLP-1 receptors in pancreatic beta cells (insulin secretion), hypothalamus (appetite suppression), gut (gastric emptying delay), and cardiovascular/renal tissues
- Reduce HbA1c, body weight, systolic blood pressure, atherogenic lipids, and hsCRP
- Direct cardiac effects proposed: anti-inflammatory, hemodynamic (reduced pericardial restraint, volume), and possible direct myocardial GLP-1 receptor signaling
Major Cardiovascular Outcome Trials (CVOTs) — Class Overview
- Class demonstrated cardiovascular superiority across multiple agents:
- Liraglutide (LEADER, T2DM high CV risk, n=9,340): MACE HR 0.87 (P=0.01 superiority)
- Semaglutide SC (SUSTAIN-6, T2DM high CV risk, n=3,297): MACE HR 0.74 (P=0.02)
- Dulaglutide (REWIND, T2DM, n=9,901): MACE HR 0.88 (P=0.026)
- Oral semaglutide (SOUL, T2DM ASCVD/CKD, n=9,650): MACE HR 0.86 (P=0.006) — first oral GLP-1 RA with CV superiority (sources/oral-semaglutide-soul-nejm-2025, rating: very high)
Nephroprotection
- Injectable semaglutide 1mg weekly (FLOW, T2DM + CKD, eGFR 47.0): kidney/CV composite HR 0.76 (P=0.0003) — first GLP-1 RA with significant nephroprotective signal in CKD
- Oral semaglutide 14mg daily (SOUL, eGFR 73.8): kidney composite HR 0.91 (P=0.19) — not significant; likely due to higher baseline eGFR and lower bioavailability (0.4–1% vs 89%) (sources/oral-semaglutide-soul-nejm-2025, rating: very high)
Oral vs Injectable Semaglutide — Key Differences
- Oral semaglutide (Rybelsus): bioavailability 0.4–1%; requires fasting administration with ≤120 ml water and 30-min pre-meal delay; max dose 14mg daily
- Injectable semaglutide (Ozempic/Wegovy): bioavailability 89%; once-weekly SC injection; doses 0.5–1mg (T2DM) or 2.4mg (obesity)
- Despite 100-fold lower bioavailability, oral semaglutide achieves equivalent MACE benefit (HR 0.86) to injectable (HR 0.74 SUSTAIN-6, HR 0.86 pooled class estimates)
- Preference: surveys show patient preference for oral over injectable, and injection hesitancy is common in T2DM (sources/oral-semaglutide-soul-nejm-2025, rating: very high)
Benefit in Heart Failure and Obesity
- Semaglutide SC 2.4mg (STEP-HFpEF, obesity + HFpEF without T2DM): KCCQ-CSS +7.8 pts; weight −10.7 pp (both P<0.001); first obesity-targeting pharmacotherapy in HFpEF (sources/semaglutide-stephfpef-nejm-2023, rating: very high)
- Tirzepatide (dual GIP/GLP-1 RA; SUMMIT, obesity + HFpEF): CV death/worsening HF HR 0.62 (P=0.026) — first hard composite benefit in obesity-HFpEF (sources/tirzepatide-hfpef-summit-nejm-2025, rating: very high)
Benefit in Liver Disease (MASLD/MASH)
- Semaglutide SC (ESSENCE phase 3): superior on both MASH histologic primary endpoints; 32.7% vs 16.1% MASH+fibrosis resolution; does not work in cirrhosis (sources/masld-nejm-2025, rating: high)
- Tirzepatide (SYNERGY-NASH phase 2b): MASH resolution 56–62% vs 44%; fibrosis reduction 51–55% vs 30% (sources/masld-nejm-2025, rating: high)
Safety Profile (Class)
- Gastrointestinal: nausea, vomiting, diarrhoea — most common; peak during dose escalation; lead to discontinuation in 6–15% depending on formulation and trial
- Gallbladder disorders: small increased risk across class
- Acute pancreatitis: low incidence; ~0.4% in SOUL; not significantly increased vs placebo
- No increased retinal disorders or malignancies at class level
- Reduced serious adverse events overall in SOUL (47.9% vs 50.3%; P=0.02) — dominated by fewer cardiac and infectious events (sources/oral-semaglutide-soul-nejm-2025, rating: very high)
Contradictions / Open Questions
- Oral vs injectable semaglutide — kidney outcomes diverge: SOUL (oral, HR 0.91 NS) vs FLOW (injectable, HR 0.76 significant). Is the lack of kidney benefit with oral semaglutide a bioavailability issue, a population issue (higher eGFR in SOUL), or a mechanistic distinction? (sources/oral-semaglutide-soul-nejm-2025, rating: very high)
- CV and renal mechanism dissociation: SOUL shows MACE benefit without kidney benefit — suggesting antiatherosclerotic and nephroprotective mechanisms may be separable and dose/exposure-dependent. (sources/oral-semaglutide-soul-nejm-2025, rating: very high)
- Mortality in HFpEF: STEP-HFpEF underpowered for hard events (3 vs 4 deaths). SUMMIT (tirzepatide) showed all-cause death HR 1.25 (NS; 19 vs 15 events) — direction concerning. Does the GLP-1 RA class reduce mortality in HFpEF, or is the benefit limited to symptoms and HF events?
- Class benefit vs weight loss benefit: Cannot disentangle direct GLP-1 receptor cardiac effects from weight loss-mediated hemodynamic benefits in HFpEF trials. SOUL's weight difference was modest (−2.95 kg) yet achieved MACE reduction, supporting direct/antiatherosclerotic mechanisms.
- Benefit in SGLT2i-treated patients: In SOUL, 26.9% were on SGLT2 inhibitors at baseline — MACE benefit was consistent in this subgroup, supporting additive rather than redundant cardioprotection. Whether the kidney benefit (when present) is additive to SGLT2i nephroprotection is less clear. (sources/oral-semaglutide-soul-nejm-2025, rating: very high)
Connections
- Related to entities/Semaglutide — injectable and oral formulations; SUSTAIN-6, SOUL, STEP-HFpEF, FLOW, ESSENCE data
- Related to entities/Tirzepatide — dual GIP/GLP-1 RA; SUMMIT; SYNERGY-NASH
- Related to entities/HFpEF — obesity-HFpEF phenotype; STEP-HFpEF and SUMMIT
- Related to entities/MASLD — MASH histologic improvement with semaglutide and tirzepatide
- Related to entities/Peripheral-Artery-Disease — SOUL: major adverse limb events HR 0.71
- Related to concepts/Cardiorenal-Syndrome — GLP-1 RA nephroprotective evidence
- Related to concepts/SGLT2-Inhibitors-in-CKD — parallel cardio-renal drug class; complementary mechanisms